SPL026 (DMT fumarate) is at the moment undergoing phase II clinical trials investigating its use along with supportive psychotherapy as a potential therapy for key depressive ailment. The hope is that the First trial, which aims to determine the lowest dose of DMT that elicits a psychedelic experience, could start https://dmt03467.blog2news.com/27520752/a-simple-key-for-dmt-unveiled